SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
SRX Global Inc. (NYSE American: SRXH) has entered into a definitive agreement to acquire CERo Therapeutics, an innovative immunotherapy company developing CER-1236, a next-generation engineered T cell therapy targeting hematologic malignancies. The acquisition will make CERo a wholly-owned subsidiary of SRX, providing enhanced capital access and op…